Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting
Business Wire•14/10/2026•16:30 ET
0
Key Highlights
- ➤Cerus to host 2026 AABB workshop on INTERCEPT Platelets and IFC
- ➤2026 AABB meeting features Cerus-sponsored workshop, oral presentations, and nine posters
- ➤INTERCEPT Blood System for cryoprecipitation approved in U.S. for producing IFC
- ➤INTERCEPT red blood cell system under European regulatory review and late-stage U.S. development
Expert Statements
Vivek Jayaraman, President and chief executive officer of Cerus
“We are pleased to highlight IFC at the 2026 AABB Annual Meeting, including an industry workshop focused on real-world experiences. The meeting provides an important opportunity to share scientific data and engage with the transfusion medicine community.”
Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting
Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the implementation and real-world experience with INTERCEPT Platelets and INTERCEPT Fibrinogen Complex, or IFC*, at the 2026 Association for the Advancement of Blood and Biotherapies (AABB) Annual Meeting, taking place in Atlanta, Georgia from October 17 through October 19. The AABB Annual Meeting attracts healthcare professionals, scientists, and other experts from around the globe involved in transfusion medicine and biotherapies.
Get started
Create a free account to read the full story.